JP2011503019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503019A5 JP2011503019A5 JP2010532485A JP2010532485A JP2011503019A5 JP 2011503019 A5 JP2011503019 A5 JP 2011503019A5 JP 2010532485 A JP2010532485 A JP 2010532485A JP 2010532485 A JP2010532485 A JP 2010532485A JP 2011503019 A5 JP2011503019 A5 JP 2011503019A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- neurturin
- protein
- neurturin protein
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 28
- 102000001839 Neurturin Human genes 0.000 claims 26
- 108010015406 Neurturin Proteins 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 17
- 229920001223 polyethylene glycol Polymers 0.000 claims 12
- 101001108441 Homo sapiens Neurturin Proteins 0.000 claims 10
- 102000052667 human NRTN Human genes 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 7
- 150000003077 polyols Chemical group 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 5
- 125000003827 glycol group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 235000013922 glutamic acid Nutrition 0.000 claims 3
- 239000004220 glutamic acid Substances 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000016222 Pancreatic disease Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07021493 | 2007-11-05 | ||
| PCT/EP2008/009320 WO2009059755A2 (en) | 2007-11-05 | 2008-11-05 | Novel neurturin conjugates for pharmaceutical use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014182466A Division JP2015057384A (ja) | 2007-11-05 | 2014-09-08 | 薬学的使用のための新規のニュールツリン複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503019A JP2011503019A (ja) | 2011-01-27 |
| JP2011503019A5 true JP2011503019A5 (enExample) | 2011-12-22 |
Family
ID=40521395
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532485A Pending JP2011503019A (ja) | 2007-11-05 | 2008-11-05 | 薬学的使用のための新規のニュールツリン複合体 |
| JP2014182466A Pending JP2015057384A (ja) | 2007-11-05 | 2014-09-08 | 薬学的使用のための新規のニュールツリン複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014182466A Pending JP2015057384A (ja) | 2007-11-05 | 2014-09-08 | 薬学的使用のための新規のニュールツリン複合体 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9029323B2 (enExample) |
| EP (1) | EP2217282A2 (enExample) |
| JP (2) | JP2011503019A (enExample) |
| KR (2) | KR20150139982A (enExample) |
| CN (2) | CN104288775A (enExample) |
| AU (1) | AU2008324426B2 (enExample) |
| BR (1) | BRPI0819220A2 (enExample) |
| CA (1) | CA2742839A1 (enExample) |
| CO (1) | CO6280503A2 (enExample) |
| CR (1) | CR11406A (enExample) |
| EA (1) | EA201070484A1 (enExample) |
| IL (1) | IL205290A (enExample) |
| MX (1) | MX2010004899A (enExample) |
| NZ (1) | NZ585262A (enExample) |
| SG (1) | SG185946A1 (enExample) |
| WO (1) | WO2009059755A2 (enExample) |
| ZA (1) | ZA201003227B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050222070A1 (en) | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
| DK1694354T3 (da) | 2003-11-27 | 2009-10-26 | Develogen Ag | Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin |
| BR112012009801A8 (pt) * | 2009-10-30 | 2016-08-30 | Cns Therapeutics Inc | Polipeptídeo neurturina e variante de neurturina |
| US9127083B2 (en) | 2009-10-30 | 2015-09-08 | Ntf Therapeutics, Inc. | Neurturin molecules |
| US8445432B2 (en) | 2009-10-30 | 2013-05-21 | Ntf Therapeutics Inc | Neurturin molecules |
| US8742677B2 (en) * | 2010-01-11 | 2014-06-03 | System General Corp. | LED drive circuit with a programmable input for LED lighting |
| CN102453725B (zh) * | 2010-11-02 | 2014-06-11 | 杭州纽龙生物科技有限公司 | 一种重组载体、包含该重组载体的重组菌株及制备方法 |
| JP6051378B2 (ja) * | 2011-05-02 | 2016-12-27 | 国立大学法人 熊本大学 | 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
| JP2003524381A (ja) * | 1998-09-22 | 2003-08-19 | ユニヴァーシティ オブ メリーランド，ボルチモア | システインノット成長因子ミュータント |
| US7442370B2 (en) * | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US20050222070A1 (en) * | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
| EP2275118A3 (en) | 2002-05-29 | 2011-10-19 | DeveloGen Aktiengesellschaft | Pancreas-specific proteins |
| ES2342397T3 (es) * | 2003-10-20 | 2010-07-06 | Nsgene A/S | Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson. |
| DK1694354T3 (da) * | 2003-11-27 | 2009-10-26 | Develogen Ag | Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin |
| EP1872790A1 (en) * | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | New formulation for increasing bioavailability of neurturin |
-
2008
- 2008-11-05 EA EA201070484A patent/EA201070484A1/ru unknown
- 2008-11-05 SG SG2012081220A patent/SG185946A1/en unknown
- 2008-11-05 CA CA2742839A patent/CA2742839A1/en not_active Abandoned
- 2008-11-05 KR KR1020157034049A patent/KR20150139982A/ko not_active Ceased
- 2008-11-05 CN CN201410282849.2A patent/CN104288775A/zh active Pending
- 2008-11-05 CN CN200880114325.5A patent/CN101848735B/zh not_active Expired - Fee Related
- 2008-11-05 WO PCT/EP2008/009320 patent/WO2009059755A2/en not_active Ceased
- 2008-11-05 BR BRPI0819220-0A patent/BRPI0819220A2/pt not_active IP Right Cessation
- 2008-11-05 AU AU2008324426A patent/AU2008324426B2/en not_active Ceased
- 2008-11-05 EP EP08848146A patent/EP2217282A2/en not_active Withdrawn
- 2008-11-05 JP JP2010532485A patent/JP2011503019A/ja active Pending
- 2008-11-05 MX MX2010004899A patent/MX2010004899A/es active IP Right Grant
- 2008-11-05 NZ NZ585262A patent/NZ585262A/en not_active IP Right Cessation
- 2008-11-05 KR KR1020107012303A patent/KR20100098619A/ko not_active Ceased
-
2010
- 2010-04-22 IL IL205290A patent/IL205290A/en not_active IP Right Cessation
- 2010-04-30 CR CR11406A patent/CR11406A/es unknown
- 2010-05-05 US US12/774,235 patent/US9029323B2/en not_active Expired - Fee Related
- 2010-05-07 ZA ZA2010/03227A patent/ZA201003227B/en unknown
- 2010-06-03 CO CO10067268A patent/CO6280503A2/es not_active Application Discontinuation
-
2013
- 2013-02-01 US US13/757,289 patent/US20130231283A1/en not_active Abandoned
-
2014
- 2014-09-08 JP JP2014182466A patent/JP2015057384A/ja active Pending
-
2015
- 2015-04-08 US US14/681,414 patent/US20160060317A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114901682B (zh) | 胰岛素衍生物 | |
| JP6066982B2 (ja) | 経口的に生物学的に利用可能な脂質ベースの構築物 | |
| US20140249093A1 (en) | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages | |
| RU2528734C2 (ru) | Новый вариант эксендина и его конъюгат | |
| TWI405581B (zh) | 蛋白質或胜肽持續釋放給藥之組合物 | |
| ES2759987T3 (es) | Una formulación líquida del conjugado de péptido insulinotrópico de acción prolongada | |
| AU2011230564B2 (en) | Methods and compositions for weight loss | |
| JP2014501762A5 (enExample) | ||
| CY1113299T1 (el) | Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο | |
| JP2010512753A5 (enExample) | ||
| JP2010031018A5 (enExample) | ||
| JP2014520798A5 (enExample) | ||
| US20170267727A1 (en) | Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors | |
| JP2015536943A5 (enExample) | ||
| JP2016516076A5 (enExample) | ||
| JP2016511752A5 (enExample) | ||
| RU2010114013A (ru) | Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств | |
| RU2010113982A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113992A (ru) | Применение урокортина и кортиколиберина в качестве терапевтических средств | |
| FI3065763T4 (fi) | Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten | |
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств | |
| WO2023143458A1 (zh) | 酰化胰岛素 | |
| JP2014500244A5 (enExample) | ||
| JP5212492B2 (ja) | 経鼻投与用医薬組成物 | |
| WO2008116913A3 (en) | Peptide compounds with transient biodegradable pegylation |